Clinical trials: Cholangiocarcinomas
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Anonymous Testing of Pathology Specimens for BRCA Mutations in Ashkenazi Jewish Individuals Who Have Cancer
The intent of the proposed study is to describe the prevalence of the most common recurring mutations in BRCA1 and BRCA2, blmAsh , and the A636P MSH2 mutation among Ashkenazi Jewish individuals with a variety of cancer diagnoses.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Lung Cancer
- Trial name
- NCT00588263
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cholangiocarcinoma, Pancreatic Cancer
Registry for Advanced Endoscopy
Observational registry including endoscopic diagnostic and therapeutic interventions in the gastrointestinal tract
- Conditions
- Cholangiocarcinoma, Pancreatic Cancer, Sclerosing Cholangitis
- Trial name
- ERDB (NCT05187312)
- Testing
- Endoscopic retrograde Cholangio- pancreatography, Endoscopic ultrasound
- Where
- Sweden
- Volunteers
- 1,000 people
- Sponsor
- Region Stockholm
Locally Advanced Solid Tumor
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion…
- Trial name
- NCT05732831
- Testing
- TNG462, Pembrolizumab
- Where
- 26 sites in United States, France and 1 more
- Volunteers
- 225 people
- Sponsor
- Tango Therapeutics, Inc.
Cervical Cancer, Colorectal Cancer
89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors
A prospective, open-label, phase 2 study to explore CAIX expression through 89Zirconium-labelled girentuximab deferoxamine (89Zr-girentuximab) PET/CT imaging in patients with solid tumors.
- Conditions
- Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- STARBURST (NCT05563272)
- Testing
- 89Zr-girentuximab for PET/CT imaging of CAIX positive tumors
- Where
- 10 sites in United States
- Volunteers
- 11 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Ltd
Melanoma (Skin Cancer), Hepatocellular Carcinoma
68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
This prospective, single-center, open-label exploratory diagnostic study aims to evaluate the safety, feasibility, and diagnostic performance of the novel Sortilin-targeted PET tracer 68Ga-SorB in patients with solid tumors.
- Conditions
- Melanoma (Skin Cancer), Hepatocellular Carcinoma, Lung Cancer, Breast Cancer
- Trial name
- SORB-PET (NCT07760012)
- Testing
- 68Ga-SorB PET/CT
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University Third Hospital
Intrahepatic Cholangiocarcinoma (Icc)
Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Cholangiocarcinoma
This study will evaluate the efficacy and safety of cryoablation combined with lenvatinib plus QL1706 (iparomlimab/tuvonralimab) in patients with advanced Intrahepatic Cholangiocarcinoma (ICC) who have progressed after first-line…
- Trial name
- CASTLE-ZS-02 (NCT07070700)
- Testing
- QL1706 (bispecific antibody targeting PD-1 and CLTA-4), Lenvatinib, cryoablation
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Fudan University
Cholangiocarcinoma, Gallbladder Carcinoma
Unilateral Stenting Versus Bilateral Stenting for Malignant Hilar Biliary Obstruction
The purpose of this study is to compare the clinical effectiveness and long-term outcomes between patients with malignant hilar biliary obstruction who are treated by unilateral or bilateral stenting.
- Conditions
- Cholangiocarcinoma, Gallbladder Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT02649712
- Testing
- biliary stent
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Xuzhou Central Hospital
Biliary Tract Neoplasms, Recurrence
A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection
The purpose of this study is to assess the difference of safety and efficacy about Capecitabine and S-1 for treatment of patients with low-risk of recurrence after BTC surgery.
- Conditions
- Biliary Tract Neoplasms, Recurrence, Cholangiocarcinoma, Gall Bladder Cancer
- Trial name
- NCT04856761
- Testing
- S-1, Capecitabine
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Fudan University
Cholangiocarcinoma
Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Tislelizumab and Regorafenib as First-Line Therapy for Advanced Cholangiocarcinoma
The goal of this clinical trial is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) combined with tislelizumab and regorafenib as first-line therapy in patients with locally advanced or…
- Trial name
- NCT07619937
- Testing
- HAIC Combined with Tislelizumab and Regorafenib
- Where
- China
- Volunteers
- 31 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Peritoneal Carcinomatosis, Peritoneal Metastases
Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer
The PIPAC NAL-IRI study is designed to examine the maximal tolerated dose of nanoliposomal irinotecan (Nal-IRI, Onivyde) administered with repeated pressurized intraperitoneal aerosol chemotherapy (PIPAC), in a monocentric, phase…
- Conditions
- Peritoneal Carcinomatosis, Peritoneal Metastases, Colorectal Cancer, Small Bowel Cancer
- Trial name
- PIPAC-NAL-IRI (NCT05277766)
- Testing
- PIPAC with Nal-IRI
- Where
- Belgium
- Volunteers
- 45 people
- Sponsor
- University Hospital, Ghent
Intrahepatic Cholangiocarcinoma
Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)
A multicenter Phase II, randomized, prospective, open-label Trial investigating the clinical impact on combining Specific Internal Radiotherapy (SIRT) with the PD1-L Inhibitor Durvalumab and the CTLA-4 Inhibitor Tremelimumab in…
- Trial name
- NCT04238637
- Testing
- Durvalumab, Tremelimumab
- Where
- 8 sites in Germany
- Volunteers
- 50 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
NRG1 Fusion, Pancreatic Cancer
Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
Merus is providing single patient/named access to the HER2/HER3 bispecific antibody, MCLA-128, to patients with advanced NRG1-fusion positive solid tumor under this early access program who are ineligible for an ongoing MCLA-128…
- Conditions
- NRG1 Fusion, Pancreatic Cancer, Non Small Cell Lung Cancer, Solid Tumor, Unspecified, Adult
- Trial name
- NCT04100694
- Testing
- MCLA-128
- Sponsor
- Merus B.V.
Cholangiocarcinoma, Chondrosarcoma
Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced solid tumors, including glioma, that harbor an IDH1 mutation.
- Conditions
- Cholangiocarcinoma, Chondrosarcoma, Glioma, Other Advanced Solid Tumors
- Trial name
- NCT02073994
- Testing
- AG-120
- Where
- 12 sites in United States, France
- Volunteers
- 174 people
- Sponsor
- Institut de Recherches Internationales Servier
Cholangiocarcinoma, Malignant Digestive System Neoplasm
Molecular Epidemiology of Biliary Tree Cancers
This study is to learn if certain risk factors (environmental, viral, behavioral, medical, and dietary), tumor markers, and genetic changes can predict the development and outcome of biliary tree cancers.
- Trial name
- NCT05179486
- Testing
- Biospecimen Collection, Questionnaire Administration
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- M.D. Anderson Cancer Center
HCC - Hepatocellular Carcinoma, Cholangiocarcinoma
A Study of GV20-0251 in Advanced or Refractory Solid Tumors
This is a single-arm, single-center study for multiple tumor indications to evaluate the safety of GV20-0251. The trial uses a 3 + 3 design and enrolls 3-6 patients in the 10 mg/kg and 20 mg/kg dose groups, respectively.
- Conditions
- HCC - Hepatocellular Carcinoma, Cholangiocarcinoma, Melanoma, NSCLC (Non-small Cell Lung Cancer)
- Trial name
- NCT07106827
- Testing
- GV20-0251
- Where
- China
- Volunteers
- 10 people
- Sponsor
- West China Hospital
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer, Pancreatic Cancer
- Trial name
- NCT00987766
- Testing
- erlotinib hydrochloride, gemcitabine hydrochloride, oxaliplatin
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Hilar Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma (Icc)
Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma (POELH-III)
In the POELH-II trial (Clinicaltrials.gov ID NCT05678218) patients with presumed resectable perihilar (pCCA), intrahepatic (iCCA) or mid-common bile duct (CBD) cholangiocarcinoma had the outcomes of their preoperative endoscopic…
- Conditions
- Hilar Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma, Perihilar Cholangiocarcinoma
- Trial name
- POELH-III (NCT07161869)
- Testing
- Registration of all findings during preoperative Endoscopic Ultrasound
- Where
- 6 sites in Netherlands
- Volunteers
- 250 people
- Sponsor
- Erasmus Medical Center
Intrahepatic Cholangiocarcinoma (Icc)
Toripalimab Combined With Gemcitabine and Cisplatin (GemCis) as Preoperative Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma
This study was a randomized controlled trial to evaluate the efficacy and safety of toripalimab combined with GemCis (gemcitabine and cisplatin) as preoperative neoadjuvant therapy for resectable ICC at high risk of recurrence.
- Trial name
- NCT06721286
- Testing
- Teripalimab, Gemcitabine + Cisplatin, Surgery
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Gemcitabine and Capecitabine in Treating Patients With Advanced and/or Inoperable Cholangiocarcinoma or Carcinoma of the Gallbladder
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00084942
- Testing
- capecitabine, gemcitabine hydrochloride
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Cholangiocarcinoma
RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy
The purpose of this study is to see if the investigational drug, RRx-001, an epigenetic agent, which turns on a number of beneficial genes that the tumor has silenced, can resensitize the tumor(s), in other words make it/them…
- Trial name
- EPIC (NCT02452970)
- Testing
- RRx-001, Gemcitabine and cisplatin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- EpicentRx, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.